Crispr Therapeutics and Vertex's Casgevy for sickle-cell disease and transfusion-dependent beta-thalassemia delivered $99 million in total revenue in the third quarter, up 30% quarter-over-quarter and nearly 6 times the prior-year period. Crispr reported a net loss of $1.15 per share.
Partnerships allow Crispr Therapeutics to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.
Crispr Therapeutics continues to burn cash to fund its research, and if clinical milestones slip or regulatory approvals fail to materialize, the path to maintainable profitability may stretch further into the future.
Metric | CRSP | MRNA | NTLA |
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.94 | 15.90 | 2.77 |
Price/Sales | 206.31 | 42.32 | 29.10 |
Price/Cash Flow | — | — | — |
Metric | CRSP | MRNA | NTLA |
|---|---|---|---|
Quick Ratio | 16.12 | 3.34 | 6.00 |
Current Ratio | 16.21 | 3.62 | 6.31 |
Interest Coverage | — | −49.00 | — |
Metric | CRSP | MRNA | NTLA |
|---|---|---|---|
Return on Assets (Normalized) | −15.62% | −20.21% | −40.65% |
Return on Equity (Normalized) | −21.49% | −31.30% | −51.53% |
Return on Invested Capital (Normalized) | −16.45% | −27.15% | −46.90% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|tHL^yB | LOCK|?lY% | $140B | |||
| Moderna Inc MRNA | LOCK|Jwv@$$ | LOCK|#d | $109B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Vy#F@T^ | LOCK|?GNF | $95B | |||
| argenx SE ADR ARGX | LOCK|^$C^%Nr | LOCK|d%C | $60B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|@J#TPQ | LOCK|z> | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|cg%Ks?l | LOCK|!Sv@ | $31B | |||
| Incyte Corp INCY | LOCK|^nzzr>D | LOCK|b^? | $25B | |||
| BioNTech SE ADR BNTX | LOCK|>j%G&% | LOCK|^@G | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%lLj&> | LOCK|$^>r | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|tPT!?!d | LOCK|D? | $16B |
United States